Police, Treatment, and Community Collaborative (PTACC)

We are thrilled to introduce the PTACC Challenge Coin! The first-ever Challenge Coin for the deflection field will be awarded to individuals who agree to take up the challenge as standard-bearers for the global field and movement of deflection. Read all about it in today's #PTACCticker: https://lnkd.in/ggQRMa42 #DeflectionLeadsTheWay #DeflectionNews #PTACC #ChallengeCoin

Last week, I had the pleasure of participating in the Annual International #Deflection & #PrearrestDiversion Summit hosted by Police, Treatment, and Community Collaborative (PTACC) in beautiful Seattle. I met some very cool #changemakers from collaborative #ATI programs big and small, from across the US and even overseas from Africa and Europe. As someone conducting her PhD dissertation research on new and early-stage programs of deflection, I was very glad I could experience these important conversations on referral-and-recovery versus arrest-and-incarceration. While my trip this time was rather short and last-minute, I plan to be back for #PTACC2025 and to catch up with more people … and, hopefully, to present some of my dissertation research findings as well!

Listening to a great panel discussion led by Jac Charlier, PTACC, great passion and leader for the deflection movement, along with Lisa Daugaard, co-architect of the Seattle LEAD (law enforcement assisted diversion) program, and Shana Merrill, Co-founder of QRT (quick response team). #PTACC

Enough said!

We're in the midst of an AMAZING #PTACCSummit2024 in Seattle, and we'll have more news in next week's Ticker! #ICYMI, here's this week's PTACC Ticker featuring opportunities and resources for #deflection partners, including our just-released guidelines for #youthdeflection! Check it out: https://lnkd.in/gdFE_rBf

And we love having Jillian Snider and Logan Seacrest and all of R Street Institute as part of the PTACC National Leadership Council and yet again, at #PTACCSummit2024 #Deflection #PTACC2024

We are always pleased to have you with us Amanda J. Peters. Your leadership in and around our field is well-recognized! #PTACCSummit2024 #Deflection #DeflectionLeadsTheWay

Great shot of the PTACC Inaugural Challenge Coin and a first for our field. Nope, can't buy them. You have to step up to the 5 points of the PTACC Deflection Challenge to get one. #PTACCSummit2024 #Deflection

Just released today in our #PTACCticker, check out our new resource on #YouthDeflection! Offering information, guidelines, and more, PTACC's campaign for youth deflection is launching this week at #PTACCSummit2024! Also in this week's Ticker, see important opportunities from the Law Enforcement Action Partnership (LEAP), a #PTACCPartner, plus opportunities from Overdose Fatality Review (OFR), the National Association of Addition Treatment Providers (NAATP), the National Institute of Justice (NIJ), and more: https://lnkd.in/gdFE_rBf #DeflectionNews #Deflection #PreArrestDiversion #StopOverdose #OverdosePrevention

LAPPA's model act on overdose reversal agents has been released! Overdose reversal agents (ORAs) are safe, non-addictive drugs that work to interrupt an overdose and save an individual’s life. As of today, the U.S. Food and Drug Administration has approved naloxone-based and nalmefene-based ORAs that each work to reverse overdoses caused by opioids. In 2024, given both the general progression of ORA laws across the country over the past three years as well as the emergence of non-prescription (i.e., over-the-counter ) options that are not yet addressed adequately in many state laws, the Legislative Analysis and Public Policy Association set out to update its 2021 model act on the topic. The provisions of the Model Overdose Reversal Agents Act (Act) https://lnkd.in/ewytW-xs intentionally push ORA access forward beyond where most, if not all, states are now. The key elements of this Act are to: (1) remove all existing restrictions about who can receive, possess, store, transfer without cost, or administer an ORA such that any “person or entity” is eligible; (2) require specified individuals and entities to offer ORAs to individuals at increased risk of overdose; (3) require emergency access to ORAs at specified locations for use by any individual; (4) provide guidelines for ORA sales, in particular sales of non-prescription ORAs; (6) grant broad immunity to people or entities for prescribing, dispensing, giving, donating, transferring without charge, selling, or administering ORAs in the absence of gross negligence, malice, or criminal intent; (7) identify the required content for educational information about ORAs and specify when that information must be disseminated; (8) require Medicaid and other health insurance coverage for ORAs, including non-prescription ORAs, and prohibit discriminatory life and health insurance practices; and (9) create a bulk overdose reversal agent purchasing fund to assist persons and entities to fulfill requirements under the Act.